MNTA Momenta Pharmaceuticals Inc.

29.75
+0.97  (+3%)
Previous Close 28.78
Open 29.26
Price To Book 7.67
Market Cap 3,488,949,338
Shares 117,275,608
Volume 1,524,685
Short Ratio
Av. Daily Volume 1,219,234
Stock charts supplied by TradingView

NewsSee all news

  1. Momenta Provides Corporate Update Amid COVID-19 Pandemic

    CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  2. Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    -- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 --

  3. Momenta Pharmaceuticals to Webcast Presentation at the Cowen 40th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  4. Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2019 Financial Results Conference Call and Webcast

    CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  5. Momenta Provides Year-End 2019 Update and 2020 Outlook

    -- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled; readout expected in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 initiation 2020.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 3Q 2020.
Nipocalimab (M281)
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
Nipocalimab (M281)
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 additional data due 2Q 2020 may not be released on time due to COVID-19.
M254
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data originally due YE 2021. Enrolment has been suspended due to COVID-19. Impact on timeline due later.
Nipocalimab (M281)
Warm Autoimmune Hemolytic Anemia (wAIHA)
Phase 2 trial to be initiated in 2021.
M254
Chronic inflammatory demyelinating polyneuropathy (CIDP)

Latest News

  1. Momenta Provides Corporate Update Amid COVID-19 Pandemic

    CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  2. Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    -- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 --

  3. Momenta Pharmaceuticals to Webcast Presentation at the Cowen 40th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  4. Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2019 Financial Results Conference Call and Webcast

    CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  5. Momenta Provides Year-End 2019 Update and 2020 Outlook

    -- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled; readout expected in

  6. Momenta Pharmaceuticals Announces CFO Transition

    CAMBRIDGE, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) ("Momenta" or the "Company"), a biotechnology company focused on discovering and developing novel biologic therapeutics to

  7. Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference.

  8. Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors. "Dr. Barlow's

  9. Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common

  10. Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the

  11. Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  12. Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results

    CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  13. Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

    CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated